UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION

COMMISSIONERS: Lina M. Khan, Chair

Rebecca Kelly Slaughter Christine S. Wilson Alvaro M. Bedoya

In the Matter of

Altria Group, Inc. a corporation;

Docket No. 9393

and

JUUL Labs, Inc. a corporation.

<u>COMPLAINT COUNSEL'S RESPONSE TO RESPONDENT ALTRIA GROUP, INC.'S</u> MOTION FOR OFFICIAL NOTICE OF TERMINATION OF THE NON-COMPETE

Respondent Altria Group, Inc.'s ("Altria") motion effectively asks the Federal Trade

Commission ("the Commission") to absolve Altria of antitrust liability for entering an illegal

Transaction four years ago because it voluntarily terminated its written non-compete with

Respondent JUUL Labs, Inc. ("JLI"). Both the Sherman Act and the Clayton Act prohibit harm

to competition—specifically, the type of harm that occurred when, as part of Altria's 35 percent

investment in JLI for \$12.8 billion (the "Transaction"), competitors Altria and JLI illegally

agreed that Altria would exit e-cigarettes and not compete against JLI in the future. Although the

written non-compete violated the antitrust laws, the anticompetitive effects of the Transaction are

not undone simply because Altria walked away from this one provision. The lost competition

between JLI and Altria has not suddenly been restored. Moreover, Altria still owns a 35 percent

stake in JLI, its former competitor in e-cigarettes, and JLI and Altria remain free to re-enter the written non-compete at any time.

Complaint Counsel does not oppose Altria's motion for official notice of its SEC Form 8- K filing. However, Complaint Counsel files this response to rebut certain flawed and misleading assertions in Altria's motion.

FACTS

In its motion, Altria mischaracterizes its illegal agreement with JLI by focusing on only one part of that agreement: the written non-compete. But the antitrust violations at issue here are much broader. Altria and JLI agreed (1) that Altria would exit its existing e-cigarette business; and (2) that Altria would not compete in e-cigarettes in the future. CC Post-Trial Br. 28; CC Post-Trial Reply Br. 49-50; CC Appeal Br. ("CCAB") 1. Altria fulfilled the agreement by removing its e-cigarette products from the market and entering into the written non-compete with JLI. CCFF ¶¶ 987-1015. Complaint Counsel has never argued that the written non-compete was the sole basis for its Sherman Act Section 1 claims; instead, Complaint Counsel has consistently argued that it should prevail even if the Commission considers *only* the written non-compete. *See* Oral Arg. Tr. 6:7-7:14; CC Post-Trial Reply Br. 50; CC Post-Trial Br. 68-72; CCAB 39 fn. 36.

ARGUMENT

I. Altria's Opt-Out of the Written Non-Compete Does Not Undo the Harm Caused by the Transaction

Altria's decision to opt-out of the written non-compete does not undo the anticompetitive effects arising from the Transaction for which Altria remains liable. It is clear from the record that with Altria's exit, consumers lost the benefits of Altria's price, innovation, and shelf space competition. CCFF ¶¶ 1527-87; CC Post-Trial Br. 60-65, 77-83; CCAB 41. The written non-compete— standing alone and while in effect—also harmed competition in the closed

system e-cigarette market. {
} the "Rolls Royce" of e-vapor products, VEEV, because it had entered the written
non- compete. CCFF ¶¶ 1651-86, 1694-96; CCAB 41. As a result, {
} was lost. Altria's opting out of the written
non-compete does nothing to remedy these past harms. And, without an Order from the
Commission, Altria and JLI could reenter this written non-compete at any time. ¹

Moreover, terminating the non-compete does not impact Altria's 35 percent equity stake in JLI, its former competitor, that it acquired as part of the Transaction. CCFF ¶¶ 33-36. The alignment of JLI and Altria's incentives alone means Altria and JLI will compete less vigorously than they would have without this common ownership. *See* CCFF ¶ 1525.

All of these anticompetitive effects remain actionable under Section 1 of the Sherman Act and Section 7 of the Clayton Act. Altria's opting out of the written non-compete now, after the competitive damage is done, does not absolve it of legal liability. The evidence shows that Altria's claim that competition has been restored is simply false.

II. Altria's Opt-Out of the Written Non-Compete Does Not Moot Antitrust Liability Under Section 1 of the Sherman Act

Altria's argument that walking away from the written non-compete moots that aspect of the Section 1 case is baseless. *See* Altria Mot. at 2. Voluntary cessation of illegal conduct does

¹ The Commission has entered orders preventing companies from re-engaging in allegedly illegal conduct. See Exhibit A, In re Axon Enterprise, Inc, et al, F.T.C. Dkt. 9389 (June 16, 2020), Press Release: FTC Approves Final Order Settling Charges that VieVu's Former Parent Company Safariland Entered into Anticompetitive Agreements with Body-Worn Camera Systems Seller Axon ("Since the Commission's complaint was issued on Jan. 3, 2020, Safariland and Axon have rescinded the non-compete and non-solicitation provisions that the complaint alleged were anticompetitive. The final order, which settles all charges against Safariland, ensures that Axon and Safariland do not enter into new agreements with similar anticompetitive provisions."), available at https://www.ftc.gov/news-events/news/press-releases/2020/06/ftc-approves-final-order-settling-charges-vievus-former-parent-company-safariland-entered; see also Exhibit B, In re Coca Cola Company, F.T.C. Dkt. 9207 (May 18, 1995), Press Release (describing Commission settlement order preventing Coca Cola Company from acquiring any rights to the Dr. Pepper brand in the United States without first obtaining Federal Trade Commission antitrust clearance for ten years), available at https://www.ftc.gov/news-events/news/press-releases/1995/05/coca-cola-company.

not moot any part of Complaint Counsel's case. See Friends of the Earth, Inc. v. Laidlaw Env't Servs. (TOC), Inc., 528 U.S. 167, 189 (2000); United States v. Concentrated Phosphate Exp. Ass'n, Inc., 393 U.S. 199, 202-203 (1968) ("Mere voluntary cessation of allegedly illegal conduct does not moot a case; if it did, the courts would be compelled to leave (t)he defendant free to return to his old ways.") (cleaned up) (citing *United States v. W. T. Grant Co.*, 345 U.S. 629, 632 (1953); O'Bannon v. Nat'l Collegiate Athletic Ass'n, 802 F.3d 1049, 1067–68 (9th Cir. 2015); United States v. Realty Multi-List, Inc., 629 F.2d 1351, 1387–88 (5th Cir. 1980) ("It is well-settled that, in a suit for injunctive relief, the voluntary cessation of allegedly illegal practices in an attempt to avoid suit does not moot the controversy they present.") (internal citations omitted). As the Supreme Court stated, "[a] case might become moot if subsequent events made it absolutely clear that the allegedly wrongful behavior could not reasonably be expected to recur;" here, however, Altria has not met this "heavy burden." Friends of the Earth, 528 U.S. at 189 (citing Concentrated Phosphate, 393 U.S. at 203). It is far from "absolutely clear" that Altria will not re-enter the written non-compete with JLI again, especially in light of its continuing ownership of the 35 percent equity stake.

CONCLUSION

For the foregoing reasons, Complaint Counsel files this response to Altria's motion.

Dated: October 24, 2022 Respectfully submitted,

s/Nicole Lindquist
Nicole Lindquist
Eric Sprague
Stephen Rodger
Peggy Bayer Femenella
James Abell
Jeanine Balbach
Michael Blevins
Erik Herron
Joonsuk Lee
Meredith Levert
Michael Lovinger
David Morris
Kristian Rodgers

Federal Trade Commission 600 Pennsylvania Avenue, NW Washington, DC 20580 Tel: (202) 326-3672 NLindquist@ftc.gov

Counsel Supporting the Complaint

EXHIBIT A



For Your Information

FTC Approves Final Order Settling Charges that VieVu's Former Parent Company Safariland Entered into Anticompetitive Agreements with Body-Worn Camera Systems Seller Axon

June 16, 2020

Tags: Competition | Bureau of Competition | Merger | Technology | Government

Following a public comment period, the Federal Trade Commission has approved a <u>final order</u> settling charges that Safariland, LLC, which manufactures and sells equipment for the law-enforcement, military, and recreational markets, entered several anticompetitive agreements with body-worn camera system seller Axon.

Safariland entered into these agreements when Axon acquired Safariland's VieVu body-worn camera systems division, the complaint alleged. According to the <u>administrative complaint</u>, the anticompetitive agreements barred Safariland from competing with Axon on all of Axon's products, limited solicitation of customers and employees by either company, and stifled potential innovation or expansion by Safariland.

<u>First announced in April 2020</u>, the settlement is part of a larger case challenging Axon's consummated acquisition of former competitor VieVu. Since the Commission's complaint was <u>issued on Jan. 3, 2020</u>, Safariland and Axon have rescinded the non-compete and non-solicitation provisions that the complaint alleged were anticompetitive. The final order, which settles all charges against Safariland, ensures that Axon and Safariland do not enter into new agreements with similar anticompetitive provisions. Litigation against Axon continues.

The Commission vote to approve the final order was 4-0-1, with Commissioner Rebecca Kelly Slaughter not participating.

The Federal Trade Commission works to <u>promote competition</u>, and protect and educate consumers. You can learn more about <u>how competition benefits consumers</u> or <u>file an antitrust complaint</u>. For the latest news and resources, <u>follow the FTC on social media</u>, <u>subscribe to press releases</u> and <u>read our blog</u>.

Press Release Reference

<u>VieVu's Former Parent Company Safariland Agrees to Settle Charges That It Entered into Anticompetitive Agreements with Body-Worn Camera Systems Seller Axon</u>

<u>FTC Challenges Consummated Merger of Companies that Market Body-Worn Camera Systems to Large Metropolitan</u>
<u>Police Departments</u>

Contact Information

Media Contact

Betsy Lordan
Office of Public Affairs
202-326-2180

Staff Contact

Lincoln Mayer
Bureau of Competition
202-326-3324

EXHIBIT B



For Release

Coca-Cola Company

May 18, 1995

The Coca-Cola Company has agreed not to acquire any rights to the Dr Pepper brand in the United States without first obtaining Federal Trade Commission antitrust clearance. Coca- Cola also will notify the FTC before acquiring any entity that has annual branded carbonated soft-drink sales over 10 million 192-ounce case equivalents. These provisions, which would be in effect for 10-years, are designed to permit the FTC to review certain soft-drink acquisitions that might substantially reduce competition and raise consumer prices, and are part of a proposed settlement of nine-year-old litigation between the FTC and Coca- Cola.

The settlement involves modifying the prior-approval and prior-notification provisions contained in an order issued by the Commission last June, and which Coca-Cola appealed to the U.S. Court of Appeals for the D.C. Circuit. Both Coca-Cola and the FTC will ask the D.C. Circuit to dismiss the appeal and send the case back to the Commission to allow the agreed upon changes to be made.

Coca-Cola is based in Atlanta, Georgia.

The modified order stems from charges filed by the FTC in federal district court in Washington, D.C. in 1986, alleging that Coca-Cola's planned acquisition of one of its largest competi- tors, the Dr Pepper Company, would violate the antitrust laws. The order would ensure that the FTC has the opportunity to review and, if necessary, to seek a court order to block potentially problematic acquisitions by Coca-Cola. Specifically, it would require Coca-Cola, for 10 years, to obtain Commission approval before acquiring:

- more -

Coca-Cola--05/18/95

- any rights to the Dr Pepper or diet Dr Pepper brand in the United States or any brand, name or trademark associated with producing, marketing, selling or distributing these brands in the United States; or
- any interest in any entity that holds, owns or otherwise controls the Dr Pepper or diet Dr Pepper brand, name or trademark in the United States.

In addition, the modified order would require Coca-Cola, for 10 years, to give the FTC advance written notice before acquiring certain large branded carbonated soft-drink manufacturers. The floor for this provision would be acquisitions by Coca-Cola of companies with sales exceeding 10 million, 192-ounce case equivalents in each of the three years preceding the transaction. Under the Hart-Scott-Rodino Act HSR Act), Coca-Cola is required to notify the FTC and the Department of Justice before acquiring more than \$15 million in assets or voting securities from an entity worth more than \$10 million. Thus, the ceiling for the modified order's prior-notification requirement would also meet HSR Act filing thresholds.

As was the case with the June 1994 order, the modified order would not affect acquisitions of bottlers by Coca-Cola. Finally, the order would include various reporting provisions designed to assist the FTC in monitoring Coca-Cola's compliance

The modified order will end the litigation that began in 1986 when the federal district court, at the FTC's request, issued a preliminary injunction to prohibit Coca-Cola from acquiring Dr Pepper pending an administrative hearing. Coca-Cola later abandoned the transaction, but refused to agree that it would not attempt the same or a similar transaction in the future. On grounds that future Coca-Cola acquisitions of branded concentrate firms could raise competitive concerns given the conditions in the soft-drink market, the Commission issued a complaint charging that Coca Cola's agreement to acquire Dr Pepper violated the antitrust laws and sought an order requiring prior-approval for certain transactions. Although Administrative Law Judge Lewis F. Parker upheld the FTC charges, he refused to enter a prior-approval order. Both complaint counsel and Coca- Cola appealed his decision to the full Commission, which again upheld the charges in a June 1994 decision. The Commission order accompanying that decision required Coca-Cola, for 10 years, to obtain Commission approval before acquiring:

- any interest in an entity that manufactures or sells branded concentrate or syrup, or that licenses the brand, name or trademark for a branded concentrate or syrup, in the United States; or
- any brand, name or trademark associated with the production, sale or distribution of branded concentrate, branded syrup or branded carbonated soft drinks in the United States.

Coca-Cola appealed the Commission decision and order to the D.C. Circuit on Aug. 26, 1994. Under the settlement, Coca-Cola and the FTC will ask the D.C. Circuit to dismiss Coca-Cola's petition for review and to remand the case back to the FTC so that the FTC can modify the June 1994 order.

The Commission vote to accept the proposed settlement for filing in court was 3-0, with Commissioners Mary L. Azcuenaga and Roscoe B. Starek, III recused.

NOTE: This agreement is for settlement purposes only and does not constitute an admission by The Coca-Cola Company that it violated the law. When the Commission issues the modified order, it will carry the force of law with respect to future actions. Each violation of such an order may result in a civil penalty of \$10,000.

Copies of proposed settlement agreement and other documents associated with this case are available from the

FEDERAL TRADE COMMISSION | OFFICE OF THE SECRETARY | FILED 10/24/2022 | DOCUMENT NO. 605962 | Page 12 LIBIL FOBLIC

FTC's Public Reference Branch, Room 130, 6th Street and Pennsylvania Avenue, N.W., Washington, D.C. 20580.

FTC Docket No. 9207

Nos. 94-1595, 94-1596, 95-1086, 95-1087 D.C. Cir.))

CERTIFICATE OF SERVICE

I hereby certify that on October 24, 2022, I filed the foregoing document electronically using the FTC's E-Filing System, which will send notification of such filing to:

April Tabor Secretary Federal Trade Commission 600 Pennsylvania Ave., NW, Rm. H-113 Washington, DC 20580 ElectronicFilings@ftc.gov

The Honorable D. Michael Chappell Administrative Law Judge Federal Trade Commission 600 Pennsylvania Ave., NW, Rm. H-110 Washington, DC 20580

I also certify that I delivered via electronic mail a copy of the foregoing document to:

Debbie Feinstein
Robert J. Katerberg
Justin P. Hedge
Francesca M. Pisano
Tanya C. Freeman
Arnold & Porter Kaye Scholer LLP
601 Massachusetts Ave, NW
Washington, DC 20001
Tel: (202) 942-5000
debbie.feinstein@arnoldporter.com
robert.katerberg@arnoldporter.com
justin.hedge@arnoldporter.com
francesca.pisano@arnoldporter.com
tanya.freeman@arnoldporter.com

David Gelfand
Jeremy J. Calsyn
Matthew Bachrack
Linden Bernhard
Jessica Hollis
Cleary Gottlieb Steen & Hamilton LLP
2112 Pennsylvania Avenue, NW
Washington, DC 20037
Tel: (202) 974-1500
dgelfand@cgsh.com
jcalsyn@cgsh.com
mbachrack@cgsh.com
lbernhardt@cgsh.com
jholis@cgsh.com

Counsel for Respondent JUUL Labs, Inc.

Beth A. Wilkinson James M. Rosenthal Hayter Whitman Megan Braun Alysha Bohanon Wilkinson Stekloff LLP 2001 M Street NW, 10th Floor Washington, DC 20036 Tel: (202) 847-4000

PUBLIC

bwilkinson@wilkinsonstekloff.com jrosenthal@wilkinsonstekloff.com hwhitman@wilkinsonstekloff.com mbraun@wiklinsonstekloff.com abonhanon@wilkinsonstekloff.com

Moira Penza
Ralia Polechronis
Meghan Cleary
Wilkinson Stekloff LLP
130 W 42nd Street, 24th Floor
New York, NY 10036
Tel: (929) 264-7773
mpenza@wilkinsonstekloff.com
rpolechronis@wilkinsonstekloff.com
mcleary@wilkinsonstekloff.com

Jonathan Moses
Kevin Schwartz
Adam Goodman
Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, NY 10019
Tel: (212) 403-1000
JMMoses@WLRK.com
KSchwartz@wlrk.com
ALGoodman@wlrk.com

Counsel for Respondent Altria Group, Inc.

By: <u>s/James Abell</u> James Abell, Attorney

Counsel Supporting the Complaint